Loading color scheme

Virtici
  • Home
  • About us
  • Focus
  • Ecosystem
  • Leadership
  • News
  • Careers
  • Contact Us
  • Aclys Bio and Genmab Enter Research and Commercial License Option Agreement to Develop Proprietary Aclys Antibodies Against an Undisclosed Target

    Aclys Bio Corp (“Aclys”), a company discovering and developing precision biologics for the treatment of cancer, earlier this month announced a new exclusive research and commercial license option agreement with Genmab A/S (Nasdaq: GMAB), an international biotech company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.

  • Celdara Medical Receives Funding to Develop Broad-Spectrum Antimicrobials for Chronic Lung Infection

    Lebanon, NH: The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) has awarded Celdara Medical, LLC a Phase I Small Business Innovation Research (SBIR) grant for development of broad-spectrum antimicrobial peptides to combat chronic lung infection in patients with cystic fibrosis (CF).

  • Javelin Oncology Hires Steven Yecies as Chief Executive Officer

    Javelin Oncology announced today that the company has hired Steven Yecies as Chief Executive Officer. Yecies brings 30 years of experience as an accomplished senior executive, consultant, and investor in the healthcare and life sciences industry.

  • Precision Medicine Leader Dennis H. Langer, M.D., J.D. Joins Javelin Oncology’s Board of Directors

    Javelin Oncology, Inc. announced today that the company has named Dennis H. Langer, M.D., J.D. to the company’s board of directors as an independent director. Dr. Langer has served as a director of several public and private health care companies, and served in leadership roles in several pharmaceutical, biotechnology and diagnostic companies.

  • Rise Therapeutics Announces FDA Clearance of its IND Application to Initiate a Phase 1 Study of an Oral Immunotherapy for the Treatment of Ulcerative Colitis

    Rockville, Maryland, January 31st, 2023 – Rise Therapeutics, a biopharmaceutical company engaged in developing novel oral synthetic biology medicines, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a Phase 1 clinical trial of its lead program candidate, R-3750.

  • Rise Therapeutics Announces Publication of an Important Peer-Reviewed Journal Article Related to its R-3750 Program

    Rockville, MD. Rise Therapeutics, a biotechnology company developing first-in-class targeted immunological-based biologics using a unique and proprietary oral delivery platform, announced today the publication of the co-authored article, “Lactococcus lactis Delivery of Surface Layer Protein A Protects Mice from Colitis by Re-Setting Host Immune Repertoire” in the journal Biomedicines.

  • Rise Therapeutics awarded $2 Million to Develop a Novel, Immunological-Directed Microbiome-based Medicine for Treatment of Sjögren’s Syndrome

    Rockville, MD. Rise Therapeutics announced today it was awarded a $2 million, multi-year grant from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program through the National Institute of Dental and Craniofacial Research (NIDCR). Grant funds will be used to develop a novel, immunologically enhanced probiotic-based therapeutic for the treatment of Sjögren’s syndrome (SS).

  • Rise Therapeutics Begins Operations of its GMP Manufacturing Facility

    Rockville, MD. Rise Therapeutics announced today that they have successfully initiated operations of their GMP manufacturing facility based in Rockville, MD.  Funding to help set up this GMP manufacturing operation came from the National Institute of Health (NIH) Commercialization Readiness Pilot (CRP) Program Grant, which assists small businesses with technical assistance and late-stage development projects that are not typically supported by SBIR and STTR Phase II and Phase IIB grants. Launching of operations for this facility was also supported by the financial contributions of the Montgomery County Economic Development Corporation.  

  • Virtici Announces Funding from NIH to Develop a New Treatment for Periodontal Disease

    Seattle, Washington - Virtici LLC announced today that the National Institute of Dental and Craniofacial Research (NIDCR) of the National Institutes of Health (NIH) has awarded a Small Business Innovation Research (SBIR) award to advance VTC-886, a first-in-class small molecule for the prevention of P. gingivalis infection.

  • 464 12th Ave, Ste 400
  • Seattle, WA 98122-5567
  • E: info@virtici.com
© 2023. All Rights Reserved. FCOI Policy
  • Home
  • About us
  • Focus
  • Ecosystem
  • Leadership
  • News
  • Careers
  • Contact Us